Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.

Oncotarget · 2011 · PMC3260002 · PMID 22081665

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In patients who received allo-SCT (n=53), there was a trend for improved outcome in DNMT3A exon 23+ patients (DFS and OS medians not reached) as compared to DNMT3A exon 23- patients (median DFS, 19.1 months, p=0.15; median OS, 29.2 months, p=0.1) but the difference did not reach statistical significance (figure 4 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.